ASSESSMENT OF A MODEL-BASED CLINICAL DECISION SUPPORT TOOL FOR BUSULFAN IN THE PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION POPULATION.

Shukla P.; Goswami S.; Keizer R. J.; Mangat R.; Long-Boyle J.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >ASSESSMENT OF A MODEL-BASED CLINICAL DECISION SUPPORT TOOL FOR BUSULFAN IN THE PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION POPULATION.

【24h】

ASSESSMENT OF A MODEL-BASED CLINICAL DECISION SUPPORT TOOL FOR BUSULFAN IN THE PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION POPULATION.

机译：儿科造血细胞移植群体母鹅基于模型的临床决策支持工具评估。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2018年第1期|共1页
作者
Shukla P.; Goswami S.; Keizer R. J.; Mangat R.; Long-Boyle J.;
展开▼
作者单位

Univ Calif San Francisco San Francisco CA 94143 USA;

InsightRX San Francisco CA USA;

InsightRX San Francisco CA USA;

InsightRX San Francisco CA USA;

Univ Calif San Francisco San Francisco CA 94143 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. ASSESSMENT OF A MODEL-BASED CLINICAL DECISION SUPPORT TOOL FOR BUSULFAN IN THE PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION POPULATION. [J] . Shukla P., Goswami S., Keizer R. J., Clinical Pharmacology and Therapeutics . 2018,第Suppla1期

机译：儿科造血细胞移植群体母鹅基于模型的临床决策支持工具评估。
2. Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant: A Model-Based Dosing Algorithm for Personalized Therapy and Implementation Into Routine Clinical Use [J] . Long-Boyle Janel R., Savic Rada, Yan Shirley, Therapeutic Drug Monitoring . 2015,第2期

机译：小儿硫丹在造血细胞移植的小儿和年轻成人患者中的群体药代动力学：用于个体化治疗的基于模型的剂量算法及常规临床应用
3. PHARMACOKINETICS AND CLINICAL OUTCOMES OF INTRAVENOUS BUSULFAN ADMINISTERED TWICE DAILY DURING CONDITIONING IN PEDIATRIC RECIPIENTS PRIOR TO FAMILIAL HAPLOIDENTICAL(FHI) T-CELL DEPLETED (TCD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AlloHSCT) IN HIGH RISK SICKLE CELL DISEASE (SCD) [J] . Mehta Brinda, Klejmont Liana, Milone Michael, Pediatric blood & cancer . 2016,第Suppla1期

机译：患儿全亲肝病（TCD）异基因造血干细胞病（TCD）完全性干细胞病性干细胞病原发性干细胞病（PC）病史前，每日两次在儿科患者接受条件治疗期间，静脉bususfan不良反应的药代动力学和临床结果
4. Intravenous Busulfan Reduces Toxicity Associated with Myeloablative Allogeneic Hematopoietic Transplantation in Patients with Myeloid Malignancies [C] . A. Shimoni, B. Bxelorai, I. Hardan, European Haematology Association . 2002

机译：静脉内的伯鲁兰减少骨髓恶性肿瘤患者患有髓鞘异产造血移植的毒性
5. Donor selection for patients undergoing allogeneic hematopoietic stem cell transplantation: Assessment of the priorities of Canadian hematopoietic stem cell transplant physicians. [D] . Tay, Jason. 2009

机译：接受同种异体造血干细胞移植的患者的供体选择：加拿大造血干细胞移植医生的优先事项评估。
6. Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant: A Model-Based Dosing Algorithm for Personalized Therapy and Implementation into Routine Clinical Use [O] . Janel Long-Boyle, Rada Savic, Shirley Yan, -1

机译：小儿硫丹在造血细胞移植的小儿和年轻成人患者中的群体药代动力学：一种基于模型的个性化治疗剂量算法并在常规临床应用中实现
7. Studying the Optimal Intravenous Busulfan Exposure in Pediatric Allogeneic Hematopoietic Cell Transplantation (alloHCT) to Improve Clinical Outcomes: A Multicenter Study [O] . Lalmohamed Arief, Bartelink Imke, van Reij Liesbeth, 2015

机译：在儿童同种异体造血细胞移植（alloHCT）中研究最佳静脉内白硫丹暴露以改善临床结果：一项多中心研究
8. Future Research Needs for Hematopoietic Stem-Cell Transplantation in the Pediatric Population. Identification of Future Research Needs From Comparative Effectiveness Review No. 48 [R] . Belinson, S., Rothenberg, B. M., Chopra, R., 2012

机译：未来研究需要在儿科人群中造血干细胞移植。从比较效力评论第48号中确定未来的研究需求

ASSESSMENT OF A MODEL-BASED CLINICAL DECISION SUPPORT TOOL FOR BUSULFAN IN THE PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION POPULATION.

著录项

相似文献

相关主题

期刊订阅